Metraipolis › archive › dc_78800a7f0bad

Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX — Europe PMC PMID:41264468

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41264468
DOI: 10.1093/oncolo/oyaf390
License (as archived): solo-consultazione
Archived: 2026-11-08T03:13:12.583Z
SHA-256 of the archived text: 48db3ec8bc822cbf4051fb4f75b512fc4a656338eb5c6445d565d18c3ce08371
Stable URL of this page: https://metraipolis.com/documento/dc_78800a7f0bad

How to cite

Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX — Europe PMC PMID:41264468 — Europe PMC (en), https://europepmc.org/article/MED/41264468 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_78800a7f0bad (Metraipolis archive dc_78800a7f0bad, sha256 48db3ec8bc822cbf4051fb4f75b512fc4a656338eb5c6445d565d18c3ce08371)

BibTeX

@misc{dc78800a7f0bad,
  title = {Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX — Europe PMC PMID:41264468},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41264468},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_78800a7f0bad; sha256 48db3ec8bc822cbf4051fb4f75b512fc4a656338eb5c6445d565d18c3ce08371},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41264468. Agents can read the archived copy with the MCP tool read_document.